Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes - A report from the Children's Oncology Group

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1415-1421

  Blanco, Javier G ^a   Sun, Can Lan ^c   Landier, Wendy ^c   Chen, Lu ^e   Esparza Duran, Diego ^c   Leisenring, Wendy ^f   Mays, Allison ^d   Friedman, Debra L ^g   Ginsberg, Jill P ⁱ   Hudson, Melissa M ^h   Neglia, Joseph P ^k   Oeffinger, Kevin C ^b   Ritchey, A Kim ^j   Villaluna, Doojduen ^e   Relling, Mary V ^h   Bhatia, Smita ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBONYL REDUCTASE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; ALCOHOL DEHYDROGENASE; ANTINEOPLASTIC ANTIBIOTIC; CBR1 PROTEIN, HUMAN; CBR3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; BONE TUMOR; CANCER DIAGNOSIS; CANCER SURVIVOR; CARDIOMYOPATHY; CASE CONTROL STUDY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE; GENETIC POLYMORPHISM; GENOTYPE; HODGKIN DISEASE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RACE; RISK; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; AGE; BIOTRANSFORMATION; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DOSE RESPONSE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; INFANT; METABOLISM; MULTICENTER STUDY; NEOPLASM; NEWBORN; PHARMACOGENETICS; PHENOTYPE; PRESCHOOL CHILD; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; SURVIVOR; TIME; UNITED STATES;

ADOLESCENT; AGE FACTORS; ALCOHOL OXIDOREDUCTASES; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; NEOPLASMS; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 81855225220     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.8987     Document Type: Article

References (32)

1. Kremer LCM, Caron HN: Anthracycline cardiotoxicity in children. N Engl J Med 351:120-121, 2004 (Pubitemid 38886645)
2. Wouters KA, Kremer LCM, Miller TL, et al: Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haematol 131:561-578, 2005 (Pubitemid 43899624)
3. Bryant J, Picot J, Levitt G, et al: Cardioprotection against the toxic effects of anthracyclines given to children with cancer: A systematic review. Health Technol Assess 11:1-84, 2007
4. Kremer LCM, van der Pal HJH, Offringa M, et al: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 13:819-829, 2002 (Pubitemid 34752678)
5. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
6. Lipshultz SE, Lipsitz SR, Sallan SE, et al: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629-2636, 2005 (Pubitemid 46179451)
7. Mordente A, Meucci E, Silvestrini A, et al: New developments in anthracycline-induced cardiomyopathy. Curr Med Chem 16:1656-1672, 2009
8. Minotti G, Menna P, Salvatorelli E, et al: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229, 2004 (Pubitemid 38720829)
9. Mushlin PS, Cusack BJ, Boucek RJ, et al: Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110:975-982, 1993 (Pubitemid 24005228)
10. Stewart DJ, Grewaal D, Green RM, et al: Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945-1952, 1993 (Pubitemid 24036310)
11. Kalabus JL, Sanborn CC, Jamil RG, et al: Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome. Drug Metab Dispos 38:2096-2099, 2010
12. Bains OS, Karkling MJ, Lubieniecka JM, et al: Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 332:755-763, 2010
13. Gonzalez-Covarrubias V, Zhang J, Kalabus JL, et al: Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos 37:400-407, 2009
14. Lakhman SS, Ghosh D, Blanco JG: Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 33:254-257, 2005 (Pubitemid 40220348)
15. Lehmann S, Isberg B, Ljungman P, et al: Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 26:187-192, 2000 (Pubitemid 30496965)
16. Granowetter L, Womer R, Devidas M, et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group study. J Clin Oncol 27:2536-2541, 2009
17. Grier HE, Krailo MD, Tarbell NJ, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003 (Pubitemid 36237038)
18. Johnson SA, Richardson DS: Anthracyclines in haematology: Pharmacokinetics and clinical studies. Blood Rev 12:52-71, 1998 (Pubitemid 28205976)
19. Gianni L, Herman EH, Lipshultz SE, et al: Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 26:3777-3784, 2008
20. Boucek RJ, Olson RD, Brenner DE, et al: The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 262:15851-15856, 1987 (Pubitemid 17165189)
21. Olson RD, Mushlin PS, Brenner DE, et al: Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 85:3585-3589, 1988
22. Mordente A, Minotti G, Martorana GE, et al: Anthracycline secondary alcohol metabolite formation in human or rabbit heart: Biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989-998, 2003 (Pubitemid 37086708)
23. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al: Genetic polymorphisms in CBR3 and NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-2795, 2008
24. Ebert B, Kisiela M, Malatkova P, et al: Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells. Biochemistry 49:8499-8511, 2010
25. Zhang J, Blanco JG: Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression. Pharm Res 26:2209-2215, 2009
26. Lakhman SS, Chen X, Gonzalez-Covarrubias V, et al: Functional characterization of the promoter of human carbonyl reductase 1 (CBR1): Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor. Mol Pharmacol 72:734-743, 2007 (Pubitemid 47347308)
27. Joerger M, Huitima AD, Meenhorst PL, et al: Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol 55:488-496, 2005 (Pubitemid 40568980)
28. Menna P, Salvatorelli E, Minotti G: Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:978-989, 2008
29. Hernán MA, Hernandez-Diaz S, Robins JM: A structural approach to selection bias. Epidemiology 15:615-625, 2004 (Pubitemid 40416916)
30. Anderson C, Nalls M, Biffi A, et al: The effect of survival bias on case-control genetic association studies of highly lethal diseases. Circ Cardiovasc Genet 4:188-196, 2011
31. Forrest GL, Gonzalez B, Tseng W, et al: Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164, 2000
32. Olson LE, Bedja D, Alvey SJ, et al: Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602-6606, 2003 (Pubitemid 37336434)